Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily doses of antiretroviral drugs. In one recent clinical study of bNAbs identified and developed into therapies at Rockefeller University, participants who received a single dose of two bNAbs maintained a nearly undetectable viral load for up to 20 weeks, and a third did so for about a year. These outcomes suggest a potential future of treatment-free, long-term control of the virus.
Continue Reading this article here
